Direava raises undisclosed round from SPARX, Nissei Capital and SBI Investment to advance physical AI for surgery
What's the deal? DireavaDealroom has a profile for this one. Try Dealroom →, a Tokyo-based startup building AI systems for surgical support, has closed a third-party allotment round from three investors: SPARX Asset ManagementDealroom has a profile for this one. Try Dealroom →, Nissei CapitalDealroom has a profile for this one. Try Dealroom →, and SBI InvestmentDealroom has a profile for this one. Try Dealroom →. The company did not disclose the amount raised.
Founded by surgeon-turned-chief executive Yushi Takeuchi, Direava plans to use the funds to advance its "physical AI" technology for surgery, expand into the US and European markets, strengthen regulatory compliance — including FDA clearance — and hire AI and medical talent.
Why now? Direava hit a key milestone at the end of 2025 when its first product, a surgical video recognition AI called Kinosula, received regulatory approval in Japan. In February 2026, it completed a proof-of-concept trial in a live operating room to validate the tool's educational value.
Nissei Capital, which has backed Direava since its seed stage, noted the company is now evolving from visual recognition into generative AI tailored for surgery — building what it describes as a "brain function" on top of the existing "eye function." Both returning investors said Direava has hit milestones on schedule, a rarity for deep-tech startups.
What could go wrong? Deploying AI in life-or-death surgical settings carries enormous regulatory and safety risks. Gathering sufficient high-quality surgical data — in both volume and detail — remains a persistent challenge. SPARX acknowledged these hurdles, noting that introducing AI into clinical environments "is by no means easy."
International expansion adds further complexity. Securing FDA approval and meeting European regulatory standards will demand significant time and capital, and competing against well-funded incumbents in the surgical robotics space — such as Intuitive Surgical — will test the startup's resources.
The signal: Direava sits at the intersection of two powerful trends: the application of AI to physical-world tasks (so-called physical AI) and the growing global shortage of skilled surgeons. The company's long-term vision — fully autonomous surgery — mirrors ambitions across industries to move AI from advisory roles into direct action.
Japan's strength in meticulous surgical technique could give Direava a data advantage as it builds training sets for its models. If it can clear the regulatory path, the startup could become an early mover in a market where AI doesn't just advise the surgeon but eventually replaces the scalpel hand entirely.
Read more: PR Times
